Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, PepGen is raising $112,499,887.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James McArthur played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About PepGen
PepGen, Inc. is a biotechnology company advancing next-generation oligonucleotide therapies for neuromuscular diseases. PepGens proprietary Enhanced Delivery Oligonucleotides (EDOs) are designed to safely and effectively target the underlying causes of rare genetic diseases such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). In preclinical studies, PepGens enhanced delivery peptides demonstrated success in cell penetration and delivery of therapeutic candidates to multiple tissue types, including cardiac tissue. PepGen was founded by leading neurology researchers in Oxford, UK and is backed by a strong syndicate of investors including RA Capital Management, Oxford Sciences Innovation (OSI), and others.

To learn more about PepGen, visit http://pepgen.com/

Contact:
James McArthur, Chief Executive Officer
703-456-8000
https://www.linkedin.com/in/james-mcarthur-b562a34/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved